UK: Avacta shareholding in AffyXell increases and Diagnostic’s division acquires Coris  

UK-based Avacta Group, a life sciences company developing targeted oncology drugs and powerful diagnostics, has announced that a second milestone equity payment has been triggered resulting in an increase in Avacta’s shareholding in AffyXell Therapeutics. Avacta’s Diagnostics division also recently completed the acquisition of Coris Bioconcept in Belgium as part of its growth strategy. South Korea…

You must be a HMI Subscriber to view this content.

Subscribe Now »